메뉴 건너뛰기




Volumn 13, Issue 3, 2008, Pages 212-219

Challenge for a better combination with basic evidence

Author keywords

Biochemical modulation; Chemotherapy; DPD; Gastric cancer; OPRT; TS

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CAPECITABINE; CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; MITOMYCIN; MITOMYCIN C; OROTATE PHOSPHORIBOSYLTRANSFERASE; OXALIPLATIN; PACLITAXEL; RAPAMYCIN; TEGAFUR; THYMIDYLATE SYNTHASE; UFT;

EID: 45749099687     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-008-0793-z     Document Type: Review
Times cited : (18)

References (55)
  • 1
    • 14944385553 scopus 로고    scopus 로고
    • Global cancer statistics in the year 2002
    • Parkin DM, Bray F, Ferlay J, et al. (2005) Global cancer statistics in the year 2002. CA Cancer J Clin 55:74-108
    • (2005) CA Cancer J Clin , vol.55 , pp. 74-108
    • Parkin, D.M.1    Bray, F.2    Ferlay, J.3
  • 2
    • 0024454042 scopus 로고
    • Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer
    • Preusser P, Wilke H, Achterrath W, et al. (1989) Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7:1310-1317
    • (1989) J Clin Oncol , vol.7 , pp. 1310-1317
    • Preusser, P.1    Wilke, H.2    Achterrath, W.3
  • 3
    • 0028032976 scopus 로고
    • Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: A prospective randomized trial of the Italian oncology group for clinical research
    • Cocconi G, Bella M, Zironi S, et al. (1994) Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian oncology group for clinical research. J Clin Oncol 12:2687-2693
    • (1994) J Clin Oncol , vol.12 , pp. 2687-2693
    • Cocconi, G.1    Bella, M.2    Zironi, S.3
  • 4
    • 0018931354 scopus 로고
    • 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer
    • Macdonald JS, Schein PS, Wooley PV, et al. (1980) 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 93:533-536
    • (1980) Ann Intern Med , vol.93 , pp. 533-536
    • MacDonald, J.S.1    Schein, P.S.2    Wooley, P.V.3
  • 5
    • 0020955894 scopus 로고
    • High dose MTX/5-Fu and adriamycin for gastric cancer
    • Klein HO, Wickramanayake PD, Dieterle F, et al. (1983) High dose MTX/5-Fu and adriamycin for gastric cancer. Semin Oncol 10:29-31
    • (1983) Semin Oncol , vol.10 , pp. 29-31
    • Klein, H.O.1    Wickramanayake, P.D.2    Dieterle, F.3
  • 6
    • 0028016155 scopus 로고
    • A phase II study in advanced gastroesophageal cancer using epirubicin and cisplatin in combination with infusion 5-fluorouracil (ECF)
    • Findlay M, Cunningham D, Norman A, et al. (1994) A phase II study in advanced gastroesophageal cancer using epirubicin and cisplatin in combination with infusion 5-fluorouracil (ECF). Ann Oncol 5:609-616
    • (1994) Ann Oncol , vol.5 , pp. 609-616
    • Findlay, M.1    Cunningham, D.2    Norman, A.3
  • 8
    • 0023726563 scopus 로고
    • Report on national wide pooled data and cohort investigation in UFT Phase II study
    • Oka K, Taguchi T, Kimura K (1988) Report on national wide pooled data and cohort investigation in UFT Phase II study. Cancer Chemother Pharmacol 22:333-338
    • (1988) Cancer Chemother Pharmacol , vol.22 , pp. 333-338
    • Oka, K.1    Taguchi, T.2    Kimura, K.3
  • 9
    • 9344248389 scopus 로고    scopus 로고
    • Antitumor activity of 1M tegafur-0.4 M 5-chloro-2,4-dihydroxypyrimidine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats
    • Shirasaka T, Nakano K, Takechi T, et al. (1996) Antitumor activity of 1M tegafur-0.4 M 5-chloro-2,4-dihydroxypyrimidine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56:2602-2606
    • (1996) Cancer Res , vol.56 , pp. 2602-2606
    • Shirasaka, T.1    Nakano, K.2    Takechi, T.3
  • 10
    • 11544323426 scopus 로고    scopus 로고
    • Preclinical antitumor efficacy of S-1; A new oral formulation of 5-fluorouracil on human tumor xenografts
    • Fukushima M, Satake H, Uchida J, et al. (1998) Preclinical antitumor efficacy of S-1; a new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol 13:693-698
    • (1998) Int J Oncol , vol.13 , pp. 693-698
    • Fukushima, M.1    Satake, H.2    Uchida, J.3
  • 11
    • 0032819756 scopus 로고    scopus 로고
    • The S-1 gastrointestinal cancer study group: An early phase II study of oral S-1, a newly developed 5-fluoruracil derivative for advanced and recurrent gastrointestinal cancers
    • Sugimachi K, Maehara Y, Horikoshi N, et al. (1999) The S-1 gastrointestinal cancer study group: an early phase II study of oral S-1, a newly developed 5-fluoruracil derivative for advanced and recurrent gastrointestinal cancers. Oncology 57:202-210
    • (1999) Oncology , vol.57 , pp. 202-210
    • Sugimachi, K.1    Maehara, Y.2    Horikoshi, N.3
  • 12
    • 0032189218 scopus 로고    scopus 로고
    • Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M Gimestat-1 M otastat potassium) in advanced gastric cancer patients
    • Sakata Y, Ohtsu A, Horikoshi N, et al. (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M Gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34:1715-1720
    • (1998) Eur J Cancer , vol.34 , pp. 1715-1720
    • Sakata, Y.1    Ohtsu, A.2    Horikoshi, N.3
  • 13
    • 6544263262 scopus 로고    scopus 로고
    • Pharmakokinetic study of S-1, a novel oral fluorouracil antitumor drug
    • Hirata K, Horikoshi N, Aiba K, et al. (1999) Pharmakokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 5:2000-2005
    • (1999) Clin Cancer Res , vol.5 , pp. 2000-2005
    • Hirata, K.1    Horikoshi, N.2    Aiba, K.3
  • 14
    • 0034029776 scopus 로고    scopus 로고
    • The S-1 gastrointestinal cancer study group: Phase II study of S-1, a novel derivative 5-fluorouracil, in advanced gastric cancer
    • Koizumi W, Kurihara M, Nakano S, Hasegawa K (2000) The S-1 gastrointestinal cancer study group: Phase II study of S-1, a novel derivative 5-fluorouracil, in advanced gastric cancer. Oncology 58:191-197
    • (2000) Oncology , vol.58 , pp. 191-197
    • Koizumi, W.1    Kurihara, M.2    Nakano, S.3    Hasegawa, K.4
  • 15
    • 0037570623 scopus 로고    scopus 로고
    • S-1 in gastric cancer: A comprehensive review
    • suppl1
    • Maehara Y (2003) S-1 in gastric cancer: a comprehensive review. Gastric Cancer 6(suppl 1):2-8
    • (2003) Gastric Cancer , vol.6 , pp. 2-8
    • Maehara, Y.1
  • 16
    • 0035033019 scopus 로고    scopus 로고
    • Pharmacogenomics: Unlocking the human genome for better drug therapy
    • McLeod HL, Evans WE (2001) Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 41:101-121
    • (2001) Annu Rev Pharmacol Toxicol , vol.41 , pp. 101-121
    • McLeod, H.L.1    Evans, W.E.2
  • 17
    • 0033569516 scopus 로고    scopus 로고
    • Pharmacogenomics: Translating functional genomics into rational therapeutics
    • Evans WE, Relling M (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487-491
    • (1999) Science , vol.286 , pp. 487-491
    • Evans, W.E.1    Relling, M.2
  • 18
    • 0029620911 scopus 로고
    • Potential of the histoculture drug-response assay to contribute to cancer patient survival
    • Kubota T, Sasano N, Abe O, et al., and the Chemosensitivity study group for the Histoculture drug-response assay (1995) Potential of the histoculture drug-response assay to contribute to cancer patient survival. Clin Cancer Res 1:1537-1543
    • (1995) Clin Cancer Res , vol.1 , pp. 1537-1543
    • Kubota, T.1    Sasano, N.2    Abe, O.3
  • 19
    • 0032837081 scopus 로고    scopus 로고
    • Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves
    • Nishiyama M, Yamamoto W, Park JS, et al. (1999) Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Clin Cancer Res 5:2620-2628
    • (1999) Clin Cancer Res , vol.5 , pp. 2620-2628
    • Nishiyama, M.1    Yamamoto, W.2    Park, J.S.3
  • 20
    • 0033090335 scopus 로고    scopus 로고
    • Dihydropyrimidine dehydrogenase, multidrug resistance-associated protein, and thymidylate synthase gene expression level can predict 5-fluorouracil resistance in human gastrointestinal cancer cells
    • Kirihara Y, Yamamoto W, Toge T, Nishiyama M (1999) Dihydropyrimidine dehydrogenase, multidrug resistance-associated protein, and thymidylate synthase gene expression level can predict 5-fluorouracil resistance in human gastrointestinal cancer cells. Int J Oncol 14:551-556
    • (1999) Int J Oncol , vol.14 , pp. 551-556
    • Kirihara, Y.1    Yamamoto, W.2    Toge, T.3    Nishiyama, M.4
  • 21
    • 0030787605 scopus 로고    scopus 로고
    • Molecular targeting of mitomycin C chemotherapy
    • Nishiyama M, Suzuki K, Kumazaki T, et al. (1997) Molecular targeting of mitomycin C chemotherapy. Int J Cancer 72:649-656
    • (1997) Int J Cancer , vol.72 , pp. 649-656
    • Nishiyama, M.1    Suzuki, K.2    Kumazaki, T.3
  • 22
    • 0033038390 scopus 로고    scopus 로고
    • Regulatory network of mitomycin C action in human colon cancer cells
    • Suzuki K, Yamamoto W, Park JS, et al. (1999) Regulatory network of mitomycin C action in human colon cancer cells. Jpn J Cancer Res 90:571-577
    • (1999) Jpn J Cancer Res , vol.90 , pp. 571-577
    • Suzuki, K.1    Yamamoto, W.2    Park, J.S.3
  • 23
    • 0036160987 scopus 로고    scopus 로고
    • 6-Methylguanine DNA methytransferase (MGMT) as a determinant of resistance to camptothecin derivatives
    • 6-Methylguanine DNA methytransferase (MGMT) as a determinant of resistance to camptothecin derivatives. Jpn J Cancer Res 93:93-102
    • (2002) Jpn J Cancer Res , vol.93 , pp. 93-102
    • Okamoto, R.1    Takano, H.2    Okamura, T.3
  • 24
    • 0035512241 scopus 로고    scopus 로고
    • Unique action determinants of double acting topoisomerase inhibitor, TAS-103
    • Okamoto R, Takano H, Sekikawa T, et al. (2001) Unique action determinants of double acting topoisomerase inhibitor, TAS-103. Int J Oncol 19:921-927
    • (2001) Int J Oncol , vol.19 , pp. 921-927
    • Okamoto, R.1    Takano, H.2    Sekikawa, T.3
  • 25
    • 0034941111 scopus 로고    scopus 로고
    • Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells
    • Yamamoto W, Verweij J, de Bruijn P, et al. (2001) Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells. Anti-Cancer Drug 12:419-432
    • (2001) Anti-Cancer Drug , vol.12 , pp. 419-432
    • Yamamoto, W.1    Verweij, J.2    De Bruijn, P.3
  • 26
    • 0030739278 scopus 로고    scopus 로고
    • Overcoming CPT-11 resistance by using a biococlaurine alkaloid, cepharanthine, to modulate plasma trans-membrane potential
    • Aogi K, Nishiyama M, Kim R, et al. (1997) Overcoming CPT-11 resistance by using a biococlaurine alkaloid, cepharanthine, to modulate plasma trans-membrane potential. Int J Cancer 72:295-300
    • (1997) Int J Cancer , vol.72 , pp. 295-300
    • Aogi, K.1    Nishiyama, M.2    Kim, R.3
  • 27
    • 17644445630 scopus 로고    scopus 로고
    • Cellular sensitivity determinants to docetaxel in human gastrointestinal cancers
    • Park JS, Yamamoto W, Sekikawa T, et al. (2002) Cellular sensitivity determinants to docetaxel in human gastrointestinal cancers. Int J Oncol 20:333-338
    • (2002) Int J Oncol , vol.20 , pp. 333-338
    • Park, J.S.1    Yamamoto, W.2    Sekikawa, T.3
  • 28
    • 0842330394 scopus 로고    scopus 로고
    • Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer
    • Koizumi W, Tanabe S, Saigenji K, et al. (2003) Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 89:2207-2212
    • (2003) Br J Cancer , vol.89 , pp. 2207-2212
    • Koizumi, W.1    Tanabe, S.2    Saigenji, K.3
  • 29
    • 18544367472 scopus 로고    scopus 로고
    • Current status and future prospects of chemotherapy for metastatic gastric cancer: A review
    • Ohtsu A (2005) Current status and future prospects of chemotherapy for metastatic gastric cancer: a review. Gastric Cancer 8:95-102
    • (2005) Gastric Cancer , vol.8 , pp. 95-102
    • Ohtsu, A.1
  • 30
    • 18544378559 scopus 로고    scopus 로고
    • Recent advances in multimodal treatment for gastric cancer: A review
    • Lordick F, Siewert JR (2005) Recent advances in multimodal treatment for gastric cancer: a review. Gastric Cancer 8:78-85
    • (2005) Gastric Cancer , vol.8 , pp. 78-85
    • Lordick, F.1    Siewert, J.R.2
  • 31
    • 0034811794 scopus 로고    scopus 로고
    • Recent advances in the treatment of gastric cancer
    • Sun W, Haller DG (2001) Recent advances in the treatment of gastric cancer. Drugs 61:1545-1551
    • (2001) Drugs , vol.61 , pp. 1545-1551
    • Sun, W.1    Haller, D.G.2
  • 32
    • 21644445993 scopus 로고    scopus 로고
    • Final results of a randomized controlled phase III trial (TAX325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC)
    • (abstract 4002). (accessed August 9, 2005)
    • Moiseyenko VM, Ajani A, Tjulandin SA, et al. (2005) Final results of a randomized controlled phase III trial (TAX325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). Proc Am Soc Clin Oncol 23:308s (abstract 4002). http://www.asco.org/ac/1,1003,_12-002511-00_18-0034-00_19- 004244,00.asp (accessed August 9, 2005)
    • (2005) Proc Am Soc Clin Oncol , vol.23
    • Moiseyenko, V.M.1    Ajani, A.2    Tjulandin, S.A.3
  • 33
    • 20044393181 scopus 로고    scopus 로고
    • Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: A randomized phase II study
    • Thuss-Patience PC, Kretzschmar A, Repp M, et al. (2005) Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. J Clin Oncol 23:494-501
    • (2005) J Clin Oncol , vol.23 , pp. 494-501
    • Thuss-Patience, P.C.1    Kretzschmar, A.2    Repp, M.3
  • 34
    • 20244364251 scopus 로고    scopus 로고
    • Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer
    • Chun JH, Kim HK, Lee JS, et al. (2005) Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer. Am J Clin Oncol 28:188-194
    • (2005) Am J Clin Oncol , vol.28 , pp. 188-194
    • Chun, J.H.1    Kim, H.K.2    Lee, J.S.3
  • 35
    • 38049047178 scopus 로고    scopus 로고
    • Capecitabine and oxaliplatin for advanced esophagogastric cancer
    • Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom et al.
    • Cunningham D, Starling N, Rao S, et al.; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36-46
    • (2008) N Engl J Med , vol.358 , pp. 36-46
    • Cunningham, D.1    Starling, N.2    Rao, S.3
  • 36
    • 33750096084 scopus 로고    scopus 로고
    • Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results
    • Kang Y, Kang WK, Shin DB, et al. (2006) Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): efficacy and safety results. ASCO Meeting Abstracts June 20:4018
    • (2006) ASCO Meeting Abstracts June , vol.20 , pp. 4018
    • Kang, Y.1    Kang, W.K.2    Shin, D.B.3
  • 37
    • 35748972266 scopus 로고    scopus 로고
    • Randomized phase III study of 5-fluorouracil (5-FU) alone versuscombination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912)
    • 18S
    • Boku N, Yamamoto S, Shirao K, et al. (2007) Randomized phase III study of 5-fluorouracil (5-FU) alone versuscombination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). Clin Oncol 25(18S):LBA4513
    • (2007) Clin Oncol , vol.25 , pp. 4513
    • Boku, N.1    Yamamoto, S.2    Shirao, K.3
  • 38
    • 40749153540 scopus 로고    scopus 로고
    • S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial
    • Koizumi W, Narahara H, Hara T, et al. (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215-221
    • (2008) Lancet Oncol , vol.9 , pp. 215-221
    • Koizumi, W.1    Narahara, H.2    Hara, T.3
  • 39
    • 45749130769 scopus 로고    scopus 로고
    • Irinotecan plus S-1(IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer: Preliminary results of a randomized phase III study (GC0301/TOP002)
    • 18S
    • Chin K, Ishii H, Imamura H, et al. (2007) Irinotecan plus S-1(IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer: preliminary results of a randomized phase III study (GC0301/TOP002). J Clin Oncol 25(18S):4525
    • (2007) J Clin Oncol , vol.25 , pp. 4525
    • Chin, K.1    Ishii, H.2    Imamura, H.3
  • 40
    • 0023187085 scopus 로고
    • Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile
    • Heggie GD, Sommadossi JP, Gross DS, et al. (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47:2203-2206
    • (1987) Cancer Res , vol.47 , pp. 2203-2206
    • Heggie, G.D.1    Sommadossi, J.P.2    Gross, D.S.3
  • 41
    • 0042062300 scopus 로고    scopus 로고
    • Gene expression in colorectal cancer and in vitro chemosensitivity to 5-fluorouracil: A study of 88 surgical specimens
    • Yoshinare K, Kubota T, Watanabe M, et al. (2003) Gene expression in colorectal cancer and in vitro chemosensitivity to 5-fluorouracil: a study of 88 surgical specimens. Cancer Sci 94:633-638
    • (2003) Cancer Sci , vol.94 , pp. 633-638
    • Yoshinare, K.1    Kubota, T.2    Watanabe, M.3
  • 42
    • 4344564478 scopus 로고    scopus 로고
    • Identification of novel genes associated with the response to 5-FU treatment in gastric cancer cell lines using a cDNA microarray
    • Park Ji-S, Yoo SY, Kim J-M, et al. (2004) Identification of novel genes associated with the response to 5-FU treatment in gastric cancer cell lines using a cDNA microarray. Cancer Lett 214:19-33
    • (2004) Cancer Lett , vol.214 , pp. 19-33
    • Park, J.-S.1    Yoo, S.Y.2    Kim, J.-M.3
  • 43
    • 0034676235 scopus 로고    scopus 로고
    • Establishment and characterization of 5-fluorouracil-resistant gastric cancer cells
    • Chung YM, Park S, Park JK, et al. (2000) Establishment and characterization of 5-fluorouracil-resistant gastric cancer cells. Cancer Lett 159:95-101
    • (2000) Cancer Lett , vol.159 , pp. 95-101
    • Chung, Y.M.1    Park, S.2    Park, J.K.3
  • 44
    • 0037660429 scopus 로고    scopus 로고
    • Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma
    • Fujii R, Seshimo A, Kameoka S (2003) Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma. Int J Clin Oncol 8:72-78
    • (2003) Int J Clin Oncol , vol.8 , pp. 72-78
    • Fujii, R.1    Seshimo, A.2    Kameoka, S.3
  • 45
    • 0242658929 scopus 로고    scopus 로고
    • Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer
    • Ichikawa W, Uetake H, Shirota Y, et al. (2003) Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer 89:1486-1492
    • (2003) Br J Cancer , vol.89 , pp. 1486-1492
    • Ichikawa, W.1    Uetake, H.2    Shirota, Y.3
  • 46
    • 33748499794 scopus 로고    scopus 로고
    • Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1
    • Ichikawa W, Takahashi T, Suto K, et al. (2006) Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. Int J Cancer 119:1927-1933
    • (2006) Int J Cancer , vol.119 , pp. 1927-1933
    • Ichikawa, W.1    Takahashi, T.2    Suto, K.3
  • 47
    • 33847342945 scopus 로고    scopus 로고
    • Overexpression of orotate phosphoribosyl transferase (OPRT) gene enhances the effect of 5-FU on gastric cancer cell lines
    • Taomoto J, Yoshida K, Wada Y, et al. (2006) Overexpression of orotate phosphoribosyl transferase (OPRT) gene enhances the effect of 5-FU on gastric cancer cell lines. Oncology 70:458-464
    • (2006) Oncology , vol.70 , pp. 458-464
    • Taomoto, J.1    Yoshida, K.2    Wada, Y.3
  • 48
    • 3242679932 scopus 로고    scopus 로고
    • Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer
    • Yoshida K, Hirabayashi N, Takiyama W, et al. (2004) Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer. Anticancer Res 24:1843-1852
    • (2004) Anticancer Res , vol.24 , pp. 1843-1852
    • Yoshida, K.1    Hirabayashi, N.2    Takiyama, W.3
  • 49
    • 33745227360 scopus 로고    scopus 로고
    • Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer
    • Yoshida K, Ninomiya M, Takakura N, et al. (2006) Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 12:3402-3407
    • (2006) Clin Cancer Res , vol.12 , pp. 3402-3407
    • Yoshida, K.1    Ninomiya, M.2    Takakura, N.3
  • 50
    • 33745955340 scopus 로고    scopus 로고
    • Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines
    • Wada Y, Yoshida K, Suzuki T, et al. (2006) Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. Int J Cancer 119:783-791
    • (2006) Int J Cancer , vol.119 , pp. 783-791
    • Wada, Y.1    Yoshida, K.2    Suzuki, T.3
  • 51
    • 3242720345 scopus 로고    scopus 로고
    • Cetuximab monotherapy and cetuximab plus irinotecan in iritenocan-refractory metastatic colorectal cancer
    • Cunningham D, Humblet Y, Siena S, et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in iritenocan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345
    • (2004) N Engl J Med , vol.351 , pp. 337-345
    • Cunningham, D.1    Humblet, Y.2    Siena, S.3
  • 52
    • 17644400134 scopus 로고    scopus 로고
    • Nuclear factor-kappaB activation correlates with better prognosis and Akt activation in human gastric cancer
    • Lee BL, Lee HS, Jung J, et al. (2005) Nuclear factor-kappaB activation correlates with better prognosis and Akt activation in human gastric cancer. Clin Cancer Res 11:2518-2525
    • (2005) Clin Cancer Res , vol.11 , pp. 2518-2525
    • Lee, B.L.1    Lee, H.S.2    Jung, J.3
  • 53
    • 33947099498 scopus 로고    scopus 로고
    • Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model
    • Sven AL, Andreas G, Gudrun E, et al. (2007) Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer 120:1803-1810
    • (2007) Int J Cancer , vol.120 , pp. 1803-1810
    • Sven, A.L.1    Andreas, G.2    Gudrun, E.3
  • 54
    • 0037020044 scopus 로고    scopus 로고
    • Identification of TOR signaling complexes: More TORC for the cell growth engine
    • Abraham RT (2002) Identification of TOR signaling complexes: more TORC for the cell growth engine. Cell 111:9-12
    • (2002) Cell , vol.111 , pp. 9-12
    • Abraham, R.T.1
  • 55
    • 0035012605 scopus 로고    scopus 로고
    • HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1-alpha (HIF-1alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression
    • Laughner E, Taghavi P, Chiles K, et al. (2001) HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1-alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21:3995-4004
    • (2001) Mol Cell Biol , vol.21 , pp. 3995-4004
    • Laughner, E.1    Taghavi, P.2    Chiles, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.